Ai Kimura

Ai Kimura

Auto-generated profile, based on publicly available information

Ai Kimura

Medical Genome Center, Research Institute, National Center for Geriatrics and Gerontology, Aichi 474-8511, Japan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Clinical Nutrition
Verified
Journal Article
Closed access
YKYoshinobu Kishino
Yoshinobu Kishino
TSTaiki Sugimoto
Taiki Sugimoto
AKAi Kimura
Ai Kimura
YKYujiro Kuroda
Yujiro Kuroda
KUKazuaki Uchida
Kazuaki Uchida
TSTakashi Sakurai
Takashi Sakurai

7 August 2021 in Neural Plasticity
Verified
Journal Article
Open access
PDF file
JSJunko Shibato
Junko Shibato
FTFumiko Takenoya
Fumiko Takenoya
THTakahiro Hirabayashi
Takahiro Hirabayashi
AKAi Kimura
Ai Kimura
MYMichio Yamashita
Michio Yamashita
SSSeiji Shioda
Seiji Shioda
The present research investigates the molecular mechanism of neurite outgrowth (protrusion elongation) under pituitary adenylate cyclase-activating polypeptide (PACAP) 38 treatments using a rat adrenal-derived pheochromocytoma cell linePC12. This study specifically looks into the regulation of PACAP38-induced collapsing response mediator protein 2 (CRMP2) previously identified in a mouse brain ischemia model and which could be recovered by PACAP38 treatment. Previously, DNA microarray analysis revealed that PACAP 38-mediated neuroprotection involved not only CRMP2 but also pathways related to glycogen synthase kinase-3β (GSK-3β) and other signaling components. Thus, to clarify whether CRMP2 acts directly on PACAP38 or through GSK-3β as part of the mechanism of PACAP38-induced neurite outgrowth, we observed neurite outgrowth in the presence of GSK-3β inhibitors and activators. PC12 cells were treated with PACAP38 being added to the cell culture medium at concentrations of 10−7M, 10−8M, and 10−9M. Post PACAP38 treatment, immunostaining was used to confirm protrusion elongation of the PC12 cells, while RT-PCR, two-dimensional gel electrophoresis in conjunction with Western blotting, and inhibition experiments were performed to confirm the expression of the PACAP gene, its receptors, and downstream signaling components. Our data show that neurite protrusion elongation by PACAP38 (10−7M) in PC12 cells is mediated through the PAC1-R receptor as demonstrated by its suppression by a specific inhibitor PA-8. Inhibitor experiments suggested that PACAP38-triggered neurite protrusion follows a GSK-3β-regulated pathway, where the AKT and cAMP/ERK pathways are involved and where the inhibition of Rho/Roc could enhance neurite protrusion under PACAP38 stimulation. Although we could not yet confirm the exact role and position of CRMP2 in PACAP38-mediated PC12 cell elongation, it appears that its phosphorylation and dephosphorylation have a correlation with the neurite protrusion elongation through the interplay of CDK5, which needs to be investigated further.

23 January 2020 in CEN Case Reports
Verified
Journal Article
Open access
PDF file
HUHiroyuki Ueda
Hiroyuki Ueda
HKHideaki Kuno
Hideaki Kuno
DTDaisuke Takahashi
Daisuke Takahashi
AKAi Katsuma
Ai Katsuma
AKAi Kimura
Ai Kimura
TYTakashi Yokoo
Takashi Yokoo
The immunoglobulin (Ig) D type is a rare variant of multiple myeloma (MM), that accounts for 1–2% of all cases. Compared to the more common types of MM, IgD MM is known to have more severe symptoms at presentation, and a poorer prognosis. A woman was admitted to our hospital for severe acute kidney disease and disorder (AKD) and back pain, and was started on hemodialysis. The renal biopsy revealed light chain cast nephropathy. She was diagnosed with IgD-λ MM based on Bence-Jones protein expression and high IgD serum levels, and started bortezomib therapy with plasma exchange (PE). After three sessions of PE, the serum free light chain levels decreased by 92%, and she was withdrawn from dialysis. The patient underwent autologous transplantation and is still in remission, demonstrating the benefits of a bortezomib-based regimen in combination with PE for IgD MM with AKD.